In vivo studies have shown that luteolin is able to block the onset of experimental allergic EAE [144] and to prevent the release of IL-1, TNF-α, and metalloproteinase-9 (MMP-9) from peripheral blood mononuclear cells (PBMCs) of MS patients [145]. The gene discussed is TNF; the disease is myeloid sarcoma.